Method of treating and preventing secondary hyperparathyroidism
The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.
1. A method of treating or preventing secondary hyperparathyroidism in Chronic Kidney Disease (CKD) Stage 3 or Stage 4 in a human patient, comprising administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies.
2. The method of claim 1 , wherein the Vitamin D repletion therapy comprises administering to the patient a compound for Vitamin D repletion selected from the group consisting of ergocalciferol, cholecalciferol, 25-hydroxyvitamin D 3 , 25-hydroxyvitamin D 2 , and combinations thereof.
3. The method of claim 2 , wherein the repletion therapy comprises administering to the patient a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
4. The method of claim 2 , wherein the compound for Vitamin D repletion is 25-hydroxyvitamin D 3 .
5. The method of claim 2 , wherein the repletion therapy comprises administering to the patient a combination of ergocalciferol and cholecalciferol.
6. The method of claim 1 , wherein the Vitamin D hormone replacement therapy comprises administering to the patient a compound for Vitamin D hormone replacement selected from the group consisting of 1,25-dihydroxyvitamin D 2 , 1,25-dihydroxyvitamin D 3 , 1,25-dihydroxyvitamin D 4 , 1α-hydroxyvitamin D 2 , 1αhydroxyvitamin D 3 , and combinations thereof.
7. The method of claim 6 , wherein the compound for Vitamin D hormone replacement is 1,25-dihydroxyvitamin D 2 .
8. The method of claim 1 , wherein the Vitamin D repletion therapy and/or the Vitamin D hormone replacement therapy comprises controllably releasing a compound for Vitamin D repletion and/or Vitamin D hormone replacement.
9. The method of claim 8 , wherein the Vitamin D repletion therapy comprises controllably releasing a compound for Vitamin D repletion.
10. The method of claim 8 , wherein the Vitamin D hormone replacement therapy comprises controllably releasing a compound for Vitamin D hormone replacement.
11. The method of claim 8 , wherein controllably releasing a compound comprises reducing the maximum serum concentration of the compound in a dose interval (Cmax) compared to an equivalent amount of the compound administered by bolus IV injection and/or an equivalent immediate-release, oral dosage form.
12. The method of claim 8 , wherein controllably releasing a compound comprises increasing the time for the plasma concentration of the compound to reach its maximum in a dose interval following administration (Tmax) compared to an equivalent amount of the compound administered by bolus IV injection and/or an equivalent immediate-release, oral dosage form.
13. The method of claim 8 , wherein controllably releasing a compound comprises decreasing the ratio of the maximum serum concentration within 24 hours after administration of the compound to the concentration 24 hours after administration (Cmax 24hr /C 24hr ) compared to an equivalent amount of the compound administered by bolus IV injection and/or an immediate-release, oral dosage form.
14. The method of claim 1 , comprising administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies to lower the patient's serum parathyroid level by at least 30%.
15. The method of claim 1 , comprising administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies to lower the patient's serum parathyroid level to the target range for the CKD stage.
16. The method of claim 1 , comprising administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies such that oversuppression of the patient's serum parathyroid hormone is avoided.
17. The method of claim 1 , where the patient does not have renal osteodystrophy.
18. The method of claim 1 , comprising administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies to increase or maintain the patient's blood level of 25-hydroxyvitamin D to at least 30 ng/mL.
19. The method of claim 1 , comprising administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies to increase or maintain the patient's blood level of 1,25-dihydroxyvitamin D to at least 25 pg/mL.
20. The method of claim 1 , comprising administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies such that the patient's blood level of 25-hydroxyvitamin D comprises predominantly 25-hydroxyvitamin D 3 .
21. The method of claim 1 , comprising administering to the patient both Vitamin D repletion and Vitamin D hormone replacement therapies to avoid supraphysiologic levels of 25-hydroxyvitamin D.